| Literature DB >> 33143065 |
Ewa Tyczkowska-Sieroń1, Tadeusz Kałużewski2, Magdalena Grabiec2, Bogdan Kałużewski2, Jacek Tyczkowski3.
Abstract
We treated Candida albicans cells with a sublethal dose of nonequilibrium (cold) atmospheric-pressure He plasma and studied alterations in the genome of this fungus as well as changes in the phenotypic traits, such as assimilation of carbon from carbohydrates, hydrolytic enzyme activity, and drug susceptibility. There is a general problem if we use cold plasma to kill microorganism cells and some of them survive the process-whether the genotypic and phenotypic features of the cells are significantly altered in this case, and, if so, whether these changes are environmentally hazardous. Our molecular genetic studies have identified six single nucleotide variants, six insertions, and five deletions, which are most likely significant changes after plasma treatment. It was also found that out of 19 tested hydrolytic enzymes, 10 revealed activity, of which nine temporarily decreased their activity and one (naphthol-AS-BI- phosphohydrolase) permanently increased activity as a result of the plasma treatment. In turn, carbon assimilation and drug susceptibility were not affected by plasma. Based on the performed studies, it can be concluded that the observed changes in C. albicans cells that survived the plasma action are not of significant importance to the environment, especially for the drug resistance and pathogenicity of this fungus.Entities:
Keywords: Candida albicans; carbon assimilation; cold plasma treatment; drug susceptibility; genome; hydrolytic enzyme activity
Mesh:
Substances:
Year: 2020 PMID: 33143065 PMCID: PMC7663045 DOI: 10.3390/ijms21218100
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The growth inhibition zone induced by plasma that was generated by the linear microdischarge jet. The red arrow indicates one of the spot colonies, which grew after plasma treatment.
Figure 2Genome diagram: (1) C. albicans SC5314 A22 ideogram; (2) control sample coverage; (3) 12_1 sample coverage; (4) 12_2 sample coverage; (5) chromosomal coordinates; (6) genomic alternations (grey—low confidence single nucleotide variants (SNVs), red—high confidence SNVs, blue—deletions, green—insertions); (7) genomic alternations statistically significant (red—high confidence SNVs, blue—deletions, green—insertions); (8) genes affected by high-confidence SNVs (red), deletion (blue), insertions (green).
Summary of statistically significant mutations detected in the tested samples.
| Standard Name | Systematic Name | Localization | Mutation | Sample 12_1 | Sample 12_2 | Description [ |
|---|---|---|---|---|---|---|
| Single Nucleotide Variants | ||||||
| TCP1 | C1_08560W_A | Chr1A:1874103 | G>C (p. Gly>Arg) | 0.0369 | 0.0095 | Chaperonin- containing T-complex subunit, induced by alpha pheromone in SpiderM medium; stationary phase enriched protein |
| Chr1A:1874104 | G>A(p.Gly>Glu) | 0.0471 | 0.0112 | |||
| Uncharacterized region | Chr1B:275481 | T>A | 0.0033 | 0.0104 | – | |
| UBP1 | C3_05870C_A | Chr3B: 1315611 | C>T (p.Gln>STOP) | 0.0208 | 0.0119 | Ortholog(s) have thiol-dependent ubiquitin-specific protease activity, role in negative regulation of protein autoubiquitination, protein deubiquitination and cytoplasm, endoplasmic reticulum localization |
| PUF3 | C4_05370W_A | Chr4B:1172318 | T>C (p.Gly>Gly) | 0.0304 | 0.0304 | RNA-binding protein involved in the regulation of mitochondrial biogenesis |
| Uncharacterized region | ChrRA:655094 | A>G | 0.0405 | 0.0082 | – | |
| Uncharacterized region | ChrRA:655095 | C>G | 0.0336 | 0.0031 | – | |
|
| ||||||
| Uncharacterized region | Chr1A:837098 | -AAAAGAAAAG | 0.0064 | 0.0428 | – | |
| Uncharacterized region | Chr2A:254001 | -TAGAAGAAGAAT | 0.0027 | 0.0345 | – | |
| Uncharacterized region | Chr2A:342691 | +C | 0.0028 | 0.0257 | – | |
| Uncharacterized region | Chr2A:239531 | -T | 0.0105 | 0.0337 | – | |
| Uncharacterized region | Chr2A:1421683 | +GATATTTAAGG | 0.0153 | 0.0256 | – | |
| Uncharacterized region | Chr3A:980388 | +T | 0.0338 | 0.0291 | – | |
| Uncharacterized region | Chr4A:686524 | -T | 0.0373 | 0.0346 | – | |
| Uncharacterized region | Chr4B:456519 | +TAAAT | 0.0185 | 0.0285 | – | |
| − | C5_03980W_A | Chr5B: 878800 | +CAACAACAA | 0.0403 | 0.0364 | Protein of unknown function; Spider biofilm induced |
| − | C7_01080C_A | Chr7A:228708 | -TC | 0.0182 | 0.0231 | Major repeat sequence (MRS) on Chromosome 7; MRS units are composed of variable numbers of RPS units flanked by HOK and RB2 sequences; found on most chromosomes; may serve as recombination hot spot |
| – | C7_02250W_A | Chr7B:490089 | +TTCCAA | 0.0022 | 0.0208 | Ortholog of |
The ability of the tested strain to absorb carbon from 19 carbohydrates, assessed using the API 20C AUX system.
| Carbohydrate | Carbohydrate Symbol | Before Plasma Treatment | After 12 × Plasma Treatment |
|---|---|---|---|
| D-glucose | GLU | + | + |
| glycerol | GLY | + | + |
| 2-keto-D-gluconate | 2KG | + | + |
| L-arabinose | ARA | − | − |
| D-xylose | XYL | + | + |
| adonitol | ADO | + | + |
| xylitol | XLT | + | + |
| D-galactose | GAL | + | + |
| inositol | INO | − | − |
| D-sorbitol | SOR | + | + |
| methyl-αD-glucopyranoside | MDG | + | + |
| N-acetyl-D-glucosamine | NAG | + | + |
| D-cellobiose | CEL | − | − |
| D-lactose | LAC | − | − |
| D-maltose | MAL | + | + |
| D-sucrose | SAC | + | + |
| D-trehalose | TRE | + | + |
| D-melesitose | MLZ | − | − |
| D-raffinose | RAF | − | − |
List of hydrolytic enzymes tested, using the API ZYM system and the characteristic wavelengths, at which the absorbance of the products of the enzymatic reactions was measured.
| No. | Enzyme | Wavelength [nm] |
|---|---|---|
| e2 | Alkaline phosphatase | 537 |
| e3 | Esterase (C4) | 537 |
| e4 | Esterase Lipase (C8) | 537 |
| e5 | Lipase (C14) | 537 |
| e6 | Leucine arylamidase | 494 |
| e7 | Valine arylamidase | 494 |
| e8 | Cystine arylamidase | 494 |
| e9 | Trypsin | 494 |
| e10 | α-Chymotrypsin | 494 |
| e11 | Acid phosphatase | 537 |
| e12 | Naphthol-AS-BI-phosphohydrolase | 582 |
| e13 | α-Galactosidase | 547 |
| e14 | β-Galactosidase | 547 |
| e15 | β-Glucuronidase | 582 |
| e16 | α-Glucosidase | 537 |
| e17 | β-Glucosidase | 537 |
| e18 | N-Acetyl-β-glucosaminidase | 454 |
| e19 | α-Mannosidase | 537 |
| e20 | β-Fucosidase | 537 |
Figure 3Activities of hydrolytic enzymes for C. albicans as a function of the number of plasma cycles.
Figure 4Summary of normalized activities of hydrolytic enzymes for C. albicans, before plasma treatment, after 12 plasma cycles, and after subsequent plasma-free screenings. All activity values for active enzymes before plasma treatment were normalized to 1.
Minimum inhibitory concentration (MIC) values (μg/mL) of antifungal agents for the investigated C. albicans strain.
| Antifungal Agent | Before Plasma Treatment [MIC Value] | After 12 × Plasma Treatment [MIC Value] |
|---|---|---|
| Voriconazole | 0.094 | 0.094 |
| Fluconazole | 2.0 | 2.0 |
| Caspofungin | 0.125 | 0.125 |
| Amphotericin B | 0.125 | 0.125 |
| Micafungin | 0.012 | 0.012 |
| Anidulafungin | 0.004 | 0.004 |
Figure 5The experimental system: (a) schematic diagram of the setup; (b) photo of the plasma razor jet.